



Science, Trust & Corporate Responsibility

David Hollinshead

AstraZeneca Global R&D

Science Policy / Science Affairs

Overview



- Science & Trust Expert Group
 - Aims, progress and next steps
- AstraZeneca Corporate Responsibility
 - Code of Conduct and research ethics
- Nanotechnology
 - Societal benefits and an industry position

March 2010

**SCIENCE AND TRUST
EXPERT GROUP REPORT
& ACTION PLAN**

Starting a National Conversation
about Good Science

Dr Aileen Allsop

*Science & Trust Expert Group
May 2010*

Our Aims:

- To enhance society's capabilities to make better-informed judgements about the sciences and their uses in order to ensure that the "licence to operate" is socially robust
- Actions for government, business, academia and other stakeholders
- 8 key aspirations focus on:
 - Communicating risk and uncertainty
 - Scientific advice
 - Business use of science
 - Commitment to ethical training
 - Building partnerships
 - Evaluation
 - Measuring and responding to public attitudes

The Group

Joint Chairs

- **Dr Aileen Allsop**, AstraZeneca
- **Dr Tony Whitehead** Government Office for Science

Members

- **Charles Blundell** Rolls-Royce
- **Professor Brian Collins** Chief Scientific Advisor, BIS
- **Dr Robert Frost**, Academy of Medical Sciences
- **Dr Tim Lewens** Lecturer in History and Philosophy of Science, University of Cambridge
- **Professor Ragnar Löfstedt** Professor of Risk Management, King's College, London
- **Professor Ann Macaskill** Professor of Health Psychology, Sheffield Hallam University
- **Professor Gordon MacKerron** Director, Sussex Science and Technology Research Unit
- **Dr Natasha McCarthy** Royal Academy of Engineering
- **Professor Maggie Pearson** Department of Health
- **Professor Steve Rayner** Institute for Science, Innovation and Society, Saïd Business School
- **Professor Michael Reiss** Institute of Education, University of London
- **Professor Dame Nancy Rothwell** University of Manchester
- **Dr Bob Sorrell** BP
- **Dr James Wilsdon** Science Policy Centre, Royal Society

What we're doing now . . .

Smaller group focusing on follow up in 5 priority areas –

- Scoping project for resource on best way to communicate what “good science” means in practice to wide range of audiences
- Developing group for business
- Planning work with universities & others to help open up research process
- Encouraging scientists to work with local communities
- Work to develop Universal Ethical Code for Scientists and

The Follow-on Group

- Joint Chairs continue
- New input from The Wellcome Trust, IDEA CETL, Society of Biology and others
- Today, potential to explore evaluation, communicating risk/uncertainty, our scoping project, and work with business
- Contact us via:
 - scienceandsociety@bis.gov.uk
 - <http://interactive.bis.gov.uk/scienceandsociety/site/trust/>
 - @scitrust on Twitter

AstraZeneca Corporate Responsibility



- Code of Conduct
 - Ensures research is conducted in accord with relevant external laws & regulations
 - Requires compliance with AZ Bioethics Policy *inter alia*
- Bioethics Policy
 - Describes commitment beyond legal compliance
 - Includes ethics standards, principles & behaviours governing R&D behaviours world-wide
- Governance
 - Science Policy & Practice Council
 - AZ Science Board
 - Regular staff CoC and bioethics training

www.astrazeneca.com/responsibility/research-ethics/

Nanotechnology – an emerging new technology



- Demonstrable life style benefits
- Significant (possibly revolutionary) advances in diagnosis or medical treatment from science on the nano scale

- AZ is not a “nanotechnology company” but uses technologies appropriate to delivering patient benefit and business need
 - formulations, targeted therapies, personalised healthcare etc
- AZ assesses the impact of all technology on patient efficacy and safety, and on health, safety and the environment, and supports appropriate investigations through external studies on the impact of nanotechnology
- Need to collaborate with competitors and others to develop joint guidance to the public, regulators, policy makers and other stakeholders on our scientific methods and interests where appropriate